Dr. Bonacker brings over 30 years of distinguished experience in the global healthcare and biotechnology industry, most recently serving as Senior Vice President and General Manager, Commercial Operations Europe at CSL Behring, where he spent 20 years leading commercial strategy and operations across global and European markets for one of the world’s leading biotherapeutics companies.
This strategic appointment strengthens Microbio’s executive leadership team as the company accelerates the global commercialisation and market expansion of InfectID™-BSI.
Dr. Bonacker graduated in pharmacy and holds a Ph.D. in Microbiology from the Max-Planck-Institute for Terrestrial Microbiology/Philipps University Marburg. Throughout his tenure at CSL Behring, he was instrumental in advancing commercial strategies for rare disease therapies, including plasma derived medicines as well as pioneering work in gene therapy and advanced therapy medicinal products (ATMPs). He has a demonstrated track record of successfully building and leading high-performing commercial teams, delivering results, driving and launching innovation and creating value across different sectors and markets .
Microbio’s Chief Executive Officer Mr. Colin Keating commented: “We are delighted to welcome Dr. Bonacker as our Chief Commercial Officer. His exceptional track record in commercialising innovative therapies for serious diseases, combined with his extensive experience in product development, European and global market access, and building world-class commercial organisations, makes him ideally positioned to lead our next phase of commercial growth and global expansion. His patient-focused approach and proven ability to deliver results align perfectly with Microbio’s mission to transform sepsis diagnosis and improve patient outcomes. With Lutz on board, we are poised to accelerate the global adoption of InfectID™-BSI and deliver on our promise to make a meaningful difference in the fight against sepsis.”
Dr. Bonacker added: “I am thrilled to join Microbio at this pivotal moment in the company’s growth trajectory. InfectID™-BSI represents a truly transformative diagnostic technology that can save lives through earlier detection and intervention in sepsis cases. The platform addresses a critical unmet medical need, and I look forward to leading our commercial efforts to ensure this innovative solution reaches patients and clinicians worldwide who need it most.”